CEO and CFO insider buying at Pacgen Life Science (V:PBS)

Christina Yip, CFO and Director, acquired 2,475,000 Common Shares on a direct ownership basis at a price of $0.060 through a prospectus or prospectus exempt offering on January 11th, 2018. The insider also acquired 2,475,000 Warrants with an exercise price of $0.060 for two years. This represents a $148,500 investment into the company's shares and an account share holdings change of 53.0%.

On the same terms, Chung-Yu Wang, CEO and Director, acquired 1,075,000 Common Shares and 1,075,000 Warrants on a direct ownership basis. This represents a $64,500 investment into the company's shares and an account share holdings change of 22.7%.

Pacgen Life Science is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

Pacgen Life Science Corporation, formerly Pacgen Biopharmaceuticals Corporation, is a life sciences company focused on the commercialization of life sciences products and services. The Company has a worldwide license to develop and commercialize an antifungal called P113 (also called PAC-113). It has sublicensed its PAC-113 right to General Biologicals Corporation (GBC), which offers non-prescription over-the-counter (OTC) products containing PAC-113 in Taiwan. P113 is a 12 amino-acid antimicrobial peptide derived from a histatin protein found in saliva. Its P113 is used for the treatment of various oral conditions, as well as vaginal, dermatological and ophthalmic conditions. GBC offers products, such as cosmetic skin-care products, oral hygiene products and intimate hygiene products. The oral healthcare product includes Mr.&Mrs.O. It has conducted a Phase IIb dose-ranging clinical trial for PAC-113. Its oral health and woman health products are in the commercialization stage.